# Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma

> **NCT02447055** · EARLY_PHASE1 · WITHDRAWN · sponsor: **Washington University School of Medicine**

## Conditions studied

- Multiple Myeloma
- Myeloma-Multiple

## Interventions

- **BIOLOGICAL:** Tocilizumab
- **DRUG:** Melphalan
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Tacrolimus
- **DRUG:** Mycophenolate mofetil
- **DRUG:** Filgrastim

## Key facts

- **NCT ID:** NCT02447055
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-12
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02447055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02447055, "Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02447055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*